Trial Profile
A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF) containing Regimens in Subjects with Chronic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 26 Jun 2022 Results assessing the comprehensive analysis of long-term bone and renal safety, presented at The International Liver Congress 2022.
- 08 Jun 2022 Long term results presented at the 2022 American Transplant Congress
- 15 Nov 2021 Long term results presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases